Oncology Markets for Tyrosine Kinase Inhibitors


oncology tyrosine kinase inhibitors  ONCOLOGY MARKETS for TYROSINE KINASE INHIBITORS  NTK522F 

 October 2021 • US$4,850 


 

Traditional cancer therapy has focused on removal or destruction of tumors cells by surgery, radiation and rather non-selective types of chemotherapy. Surgery and radiation are often effective with tumors which are localized and have not metastasized to multiple sites throughout the body. Intensive research and clinical trial activity have led to a number of targeted treatments, using novel pathways and signaling, that have achieved results representing a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. One promising area is a class of drugs known as tyrosine kinase inhibitors, which  phosphorylate specific amino acids on substrate enzymes, changes that subsequently alter signal transduction leading to downstream changes in cellular biology. This report examines and analyzes the three dozen therapeutic drugs that are defining the TKI oncology space.

oncology tyrosine kinase inhibitors

 
     
                
 
 
 
 

What You Will Learn

• What is the market share of approved TKI therapeutics?
• What is the global supply picture for targeted TKI therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic TKI coverage across all oncology indications?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive TKI picture for the major Oncology market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation TKI therapeutics?

 

Tyrosine Kinase Inhibitors – Summary of Contents

Executive Summary

Biological Drug Market Dynamics

Targeted Oncology

Tyrosine Kinase Inhibitors

Breast Cancers

TKI Therapeutics – Breast Cancer (Two Approved TKIs)

Breast Cancers – Clinical Trial Activity

Breast Cancers – Market Data

Gastrointestinal Cancers

Gastric Cancer

Gastrointestinal Carcinoid Tumors

Gastrointestinal Stromal Tumors

TKI Therapeutics  – Gastrointestinal Cancers (Three Approved TKIs)

Hematology Cancers

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia

TKI Therapeutics – Hematology Cancers

TKI Clinical Trial Activity – Hematology Cancers (Seven Approved TKIs)

Leukemias

Lymphomas

Myeloma

Hematology Cancers – Market Data

Lung Cancers

Non-small Cell Lung Cancer

Small Cell Lung Cancer

TKI Therapeutics – Lung Cancers (Thirteen Approved TKIs)

Clinical Trial Activity – Lung Cancers

Market Data

Melanoma

TKI Therapeutics – Melanoma (Three Approved TKIs)

Melanoma – Clinical Trial Activity

Melanoma – Market Data

Renal Cell Carcinoma

TKI Therapeutics – Renal Cell Carcinoma (Three Approved TKIs)

Renal Cell Carcinoma – Clinical Trial Activity

Renal Cell Carcinoma – Market Data

Thyroid Cancers

TKI Therapeutics – Thyroid Cancers (Five Approved TKIs)

Thyroid Cancers – Market Data